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2012.08.0Abstract Schistosoma-associated bladder cancer was believed, for several decades, to be a com-
pletely unique entity of disease, different from urothelial cancer. This was probably due to its dis-
tinct clinicopathologic and demographic features that varied from those of urothelial entity. The
carcinogenesis is an extremely complex process resulting from the accumulation of many genetic
and epigenetic changes leading to alterations in the cell proliferation regulation process. In bladder
cancer, many of these carcinogenic cascades were not fully documented or somewhat conﬂicting.
Inspite of the efforts performed, much is still needed to explore the presence or absence of the car-
cinogenic difference with a different etiology. The control of schistosomiasis in certain countries
and the subsequent decrease in the intensity of infestation showed changing of features approaching
that of urothelial tumors. However the schistosoma-associated bladder cancer presented in more
advanced stages than schistosoma-non associated urothelial cancer. More recently, data are gath-
ered that, upon applying the same treatment protocol and management care, stage by stage com-
parison of the treatment end-results were found to be similar in bladder cancer patients with a
different etiology. All treatment options; including radical cystectomy with or without adjuvant
or neoadjuvant chemo- or radiotherapy or trimodality bladder preserving treatment seem to lead
to similar end-results regardless of etiologic factor(s) implicated in bladder cancer development.
ª 2012 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
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Bladder cancer is an important worldwide health problem with
a global estimate of 386,300 new cases and 150,200 deaths in
the year 2008. The majority of bladder cancer occurs in males
and there is a 14-fold variation in incidence internationally.
The highest incidence rates are found in the countries of Eur-
ope, North America, and Northern Africa [1]. It is estimated
that one in 26 males and one in 87 females in USA will develop
bladder cancer during their life time [2]. Smoking and occupa-
tional exposure are the major risk factors in Western countries,
while chronic infection with Schistosoma Hematobium (SH) in
developing countries, particularly in Africa and the Middle
East, accounts for the main total burden [3].
Superﬁcial (non-muscle invasive) category represents the
majority of bladder cancer population while around 20–40%
of the patients will present with or subsequently develop inva-
sive cancer. Bladder cancer is morphologically heterogeneous;
more than 90% of bladder cancer cases are urothelial (UC,
transitional cell, TCC] carcinoma, whereas primary squamous
cell carcinoma (SCC), adenocarcinoma, small cell carcinoma
and other rare tumors are less common [4]. Urothelial cell car-
cinomamay present in a mixed form with other malignant com-
ponents including squamous differentiation (present in 20–
60% of bladder cancer cases), adenocarcinoma or glandular
differentiation (10%), sarcomatoid (7%), micropapillary
(3.7%) and lymphoepı`telioma-like carcinoma. In many devel-
oping countries, life expectancy is much lower than in western
countries, which may lead to a lower BC incidence (not age-spe-
ciﬁc incidence) in these developing countries [2]. Bladder cancer
is associated with substantial morbidity and mortality. History
of Tobacco smoking not only increases the incidence of BC, but
also it can increase the tumor grade, its size and the tumor num-
ber [5]. Chronic schistosomal cystitis was related for a long per-
iod to the development of BC in areas endemic for
schistosomiasis like Egypt. In these areas, risk factors are
many, including exposure to schistosomiasis, increased smok-
ing rate and exposure to many carcinogenic chemicals [6].
There was an increasing incidence of bladder cancer, in
spite of the reduction in smoking in the United States, this sug-
gests that other environmental factors may be playing an
increasing role in the development of this cancer. Contrarily,
there was a 5.14% decrease in the death rate due to bladdercancer in USA, between 1990 and 2007 [2], due to the success
in management.
Bladder cancer formation
Urothelial tumor is characterized by its multifocality. The
modern carcinogenesis model suggests that malignancy repre-
sents clonal expansion of one or a few cancer stem cells that
proliferate through asymmetric differentiation and can diver-
sify into heterogeneous cancer cell lineages. Following cell divi-
sion, one daughter cell retains the capacity to divide again and
the other daughter cell possesses genetic plasticity, allowing
phenotypic variation in the offspring. When tumors arise from
Chromosomal Somatic Changes (CSC) of progenitor cells, a
speciﬁc set of genomics, epigenomic and/or microenvironment
niche alterations is essential for continued clonal expansion.
Therefore, each CSC and its pro/zaxgency possess a unique
set of genetic, epigenetic and phenotypic features. Genetic
alterations of stromal somatic cells assist CSCs in the niche
to promote cancer development and progression [7].
Schistosomia Hematobium and its relation to bladder cancer
According to the World Health Organization (WHO), schisto-
somiasis infect 200 million people and is endemic in as much as
76 tropical developing countries. Schistosomes are parasitic
blood ﬂukes, which have a mammalian host and an intermedi-
ate invertebrate host: fresh water snails [8,9]. There are four
human schistosomes: S. haematobium, Schistosoma Mansoni,
Schistosoma Japonicum, Schistosoma Mekongi. S. Haematobi-
um (SH) is the one associated with bladder cancer. The SH,
like other schistosomes is dioecious as the adult female lives
in-copulo in the gynecophoral canal of the male; and lives in
the venules of the human urinary bladder. Eggs laid in the uri-
nary bladder produce irritation and tissue ﬁbrosis, that may
contribute to the development of human carcinogenicity [10].
All schistosoma infections follow direct contact with fresh
water that harbors free-swimming larval forms of the parasite
known as cercariae. Cercariae penetrate the skin. The cercariae
shed their bifurcated tails, and the resulting schistosomula en-
ter capillaries and lymphatic vessels en route to the lungs. The
worms migrate to the portal venous system, where they mature
and unite. Worms then migrate to the vesical plexus and veins
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infection and continues for 3–5 years. Eggs pass from the
blood vessels lumen into adjacent tissues, and then through
the bladder mucosa to shed in the urine. The life cycle is com-
pleted when the eggs hatch; releasing miracidia that, in turn,
infect speciﬁc fresh water snails (Bulinus species). After two
generations––primary and then daughter sporocysts, within
the snail, cercariae are released [11].
Schistosomiasis was ﬁrst linked to urinary bladder cancer
by Furgesson in Egypt in 1911 [12]. The incidence of urinary
bladder cancer in the Middle East and Africa is greater in areas
with high rather than low SH prevalence. The overall preva-
lence of SH infection in Egypt was 37–48% that decreased
due to the antibilharzial campaign to 3% [13]. The urinary
bladder cancer previously accounted for about 31% of the to-
tal incidence of cancers in Egypt that subsequently decreased
to 12% in recent years. [14]. There are several factors that
may contribute to the oncological potential of schistosomia
infection. The ova deposited in the bladder provoke an intense
inﬂammatory reaction, associated with the production of oxy-
gen-derived free radicals, which may induce genetic mutations
or promote the production of carcinogenic compounds (such
as N-nitrosamines and polycyclic aromatic hydrocarbons)
[15,16], leading to malignant transformation. It is known that
schistosomiasis is often accompanied by chronic bacterial
super-infection, which may in itself predispose to squamous
cell (SC) neoplasia [17]. Bacteria that usually accompany schis-
tosomiasis can promote the formation of N-nitrosamines.
International Agency for Research on Cancer (IARC) found
that the intensity of infection is determined by urinary egg
counts and compounded by smoking, and the combination
was strongly considered. Positive association between bladder
cancer and SH infection was detected, with odd ratios ranging
from 2 to 14 [18].
Pathology of schistosomiasis and SA-BC
The pathological ﬁndings of schistosomiasis are mainly due to
inﬂammatory and immunological responses to egg deposition.
Granulomatous areas form around the eggs and induce an
exudative cellular response consisting of lymphocytes, poly-
morphonuclear leukocytes and eosinophil. The peri-oval gran-
ulomas, ﬁbrosis and muscular hypertrophy are detected
histologically. In the urinary bladder, masses of large granu-
lomatous inﬂammatory polyps containing eggs are found at
urinary bladder walls. Polyps may ulcerate and slough, pro-
ducing hematuria. Bladder ulcers, sandy patches, irregularly
thickened or atrophic bladder mucosa, ﬁbrosis and granulo-
mas containing calciﬁed or disintegrated eggs were also seen
[19]. The response to egg deposition could lead to calciﬁcation
of the urinary bladder, infection, stone formation and mucosal
proliferation [20].
Carcinogenesis of chronic schistosomal infection
Efforts have been made to study the speciﬁc genes involved in
the induction of SA-BC. Cell exposed to SH cell total antigen
(worm extract) was found to divide faster than those not ex-
posed to the antigen and died much less, probably due to the
increased level of bcl2 [21]. Murine urothelium exposed to
SH total antigen showed dysplasia, low grade intra-urothelialneoplasm, non-invasive malignant ﬂat lesions in 70% of the
tested mice. Bladder carcinoma harbors gene mutations that
constitutively activate the receptors tyrosine kinase Ras path-
way [22]. Botelho et al. [23] suggested that the parasite extract
has carcinogenic ability possibly through oncogenic mutation
of Kras gene.
Among the most common genetic changes in bladder can-
cer is the loss of heterozygosity (LOH) on chromosomes 9p
and 9q, which is found regardless of tumor grade and stage
[24,25]. No line of demarcation between schistosomiasis-asso-
ciated and non schistosomiasis-associated bladder cancer was
detected in terms of LOH of microsatellite markers on chro-
mosome 9. This suggests that data obtained from SA-BC
can be extrapolated to bladder cancer induced by other etio-
logic mechanism [26]. Bladder cancer is a very heterogeneous
disease cytogenetically, which suggests that the pathogenesis
of the disease may not be consistent for every case. The over-
expression of the BCL-2 gene in SA-BC patients was found to
be up-regulated in squamous but not transitional cell cancers.
Therefore, this BCL-2 overexpression is consistent with the
predominance of SCC in SA-BC. Mutations of TP53 were de-
tected in 73% of tumors, BCL-2 expression in 32% and abnor-
malities of both TP53 and BCL-2 in 13% [27].
Furthermore, cyclooxygenase-2 is overexpressed in SA-BC.
The cyclooxygenase-2 role in the complex multi-stage process
of SA-BC carcinogenesis was proposed: pro-inﬂammatory
cytokines such as interleukin-1, tumor growth factor-B and tu-
mor necrosis factor-alpha. H-RAS, deletion of p16 and p15,
increased epidermal growth factor receptor, c-erb-2 and tumor
necrosis factor-alpha are additional mutation reported. These
changes increase tumorigenicity by decreasing cell apoptosis
and/or creating immunosuppression. Prostaglandin products
of cyclooxygenase-2 cause tumor progression and eventual
metastasis by down-regulating adhesion molecules, increasing
the degradation of extracellular matrix and increasing angio-
genesis [28].
Schistosoma-associated bladder cancer (SA-BC)
The association between SA-BC and SH was initially estab-
lished through case-controlled studies and through the close
correlation of the incidence of bladder cancer with the preva-
lence of SH within different geographic areas. The association
was based on the frequent association of tumors with the pres-
ence of parasitic eggs and egg-induced granulomatous pathol-
ogy involving bladder tissues. However, there is yet, no clearly
deﬁned cellular mechanisms linking SH infestation with blad-
der cancer formation.
SA-BC was known by characteristic pathology (i.e. squa-
mous carcinoma, transitional cell carcinoma, or adenocarci-
noma, rather than predominantly transitional) and cellular
and molecular biology that may differ from non-schisto-
soma-associated bladder cancer (NSA-BC). The cytogenetic
and molecular genetic abnormalities were scarcely studied in
SA-BC. Some compared DNA copy number changes in SA-
BC and NSA-BC [5,6,29,30]. Muscheck et al. [5] demonstrated
deletion similarities in Schistosoma-associated transitional cell
carcinoma (SA-TCC) and Schistosoma-associated squamous
cell carcinoma (SA-SCC), compared to what has been previ-
ously reported by Kallioniemi et al. [6] on SNA-TCC and
Tsutsumi et al. [29] on SNA-SCC. Armengol et al. [30] in pools
154 M.S. Zaghloulof tissue arising from patients having similar pathological sub-
types revealed recurrent primary changes that prevail in each
subtype, The pooled specimens of SA-BC tumors showed no
schistosomiasis speciﬁc changes, compared with pools of
NSA tumors. The comparison between SA-TCC and SNA-
TCC and that between SA-SCC and SNA-SCC were similar.
DNA copy number proﬁles of urinary bladder SA adenocarci-
noma revealed similarities to those of SA-TCC and SA-SCC
[32]. Detailed individual gene analysis revealed a set of genes
with the same copy number changes in all bladder carcinomas,
including both SA and SNA tumors. There were no major
cytogenetic differences among different urinary bladder epithe-
lial tumors, regardless of the suspected predisposed carcinogen
[31]. Abnormlities in chromosomes 1, 3, 5, 7, 9 and 17 are the
most frequently involved chromosomes in urothelial bladder
cancer [33]. In a recent study Aly et al. [35] using FISH tech-
nique proved changes in SA-BC. This was previously detected
using CGH technique in SA-BC together with aberrations in
chromosomes 3, 4, 5, 6 and 11 [4,34]. It was found that the
most commonly found chromosomal deletion in all stages in
SA and SNA-BC involves deletions in chromosome 9
[24,25,35], resulting in the loss of there gene encoding proteins
that activate the Rb and P53 tumor suppressor pathways. Fur-
thermore, chromosome 9 harbors the TSC1 tumor suppressor
that down-regulates the antiapoptotic Akt/mTOR pathway
[36]. Therefore, deletions on one chromosome may have a cru-
cial inﬂuence on the initial steps in tumor development. Fur-
thermore, these mutations may overactivate the ﬁbroblast
growth factor receptor 3 protein, which likely directs bladder
cells to grow and divide abnormally leading to the formation
of bladder tumor [35]. This suggested that cytogenetic proﬁles
of chemical- and Schistosoma-induced carcinoma are largely
similar [5,30,31]. The decreased intensity of schistosomal infes-
tation in Egypt led to a changing pattern of the clinicoepidem-Table 1 The 5-year survival of each pathological stage in schistos
patients in large series of radical cystectomy.
Author Patients # PT1
SNA-BC (Pure Urothelial Carcinoma)
Cheng et al., [46] 218 —
Stein et al., [60] 1054 74
Medersbacher et al., [100] 507 76
Takahashi et al., [63] 466 81
Dhar et al., [91] 385 —
Ho et al., [101] 148 77
Manoharan et al., [92] 432 79
Abdollah et al.[93] 11697 80
Lughezzani et al. [94] 11260 61 5
SNA-BC (Urothelial & Non-urothelial)
Nishiyama et al., [95] 1113 82 8
Niu et al., [96] 356 —
Gupta et al.,[48] 502 90
Abdollah et al.[93] 614 75
SA-BC (Urothelial & Non-urothelial)
Ghoneim et al., [52] 1026 73 6
El Mekresh et al., [97] 185 83
Khaled et al., [98] 180 55
Zaghloul et al., [73] 192 100 1
Zaghloul et al., [99] 216 100 5
Ghoneim et al., [53] 2720 82 7
* = a/b, NM= not mentioned.iologic features of SA-BC. The reported clinicoepidemiologic
differences between SA-BC and SNA-BC are now continu-
ously minimizing and the features of SA-BC are slowly
approaching those of SNA-BC as reported by Koraitim
et al. [37] and Zaghloul et al. [38]. If these changes continue,
SA-BC is expected to become identical in features to that of
western countries SNA-BC [4,38,39].
Prognostic inﬂuence of chromosomal aberrations
The prognostic value of these aberrations was not totally clear.
One study denoted a prognostic value for chromosome 4
abnormalities [35]. However, the whole genome analyses
showed that low stage low grade tumors generally show fewer
changes than higher stages and grades. Furthermore, several
genomic alterations were shown to be highly speciﬁc for more
aggressive tumors. Morphologically normal urothelium in
bladder cancer patients frequently show the same type of geno-
mic alterations as the tumor itself. This makes an issue of to
what extent information on genomic changes will produce reli-
able prognostic information [35].
Clinical presentation
Clinical presentations in SA-BC and SNA-BC are similar with
few minor differences. Hematuria, dysuria and necroturia are
the main symptoms in both situations. However, SA-BC pa-
tients usually had previous history of such symptoms as a re-
sult of simple schistosomal cystitis and this may be the
reason of their relatively late presentation. The early stages
(Pa, Pis, P1) were fewer in SA-BC than those in SNA-BC (uro-
thelial and non-urothelial). The pelvic nodal involvement was
nearly similar in SA-BC (range: 16.7–25.5%), urothelial SNA-oma-non associated and schistosoma-associated bladder cancer
PT2 PT3 PT4 Nodal Involvement
50 28 17 11
81/68* 47 44 35
62 40 49 26
74 47 38 50
63 19 NM 9
68 65 11 37
60 43 17 22
51
7 49 47 39
4/69* 59 43 35
73/44* 22 0 8
78 70/58* 46 NM
53.7
6 47/31* 19 23
41 21
12 6
00/47 40 44 31
1 40 30 31
5/53 40 30 27
Bladder cancer and schistosomiasis 155BC (range: 16.3–45%) and non-urothelial SNA-BC (21.8–
23%). The clincopathologic differences between SA-BC and
SNA-BC were previously summarized as: late presentation,
younger median age and a higher percentage of squamous cell
carcinoma [40]. Distant metastases are similar in SA-BC and
SNA-BC including the different histopathological variants.
In a study that included 357 SA-BC patients, the 5-year inci-
dence of distant metastasis was 23%. The 5-year actuarial inci-
dence of distant metastasis varied according to the tumor cell
type. Squamous cell carcinoma led to a distant metastasis inci-
dence rate of 15% at 5 years compared to 39% for TCC and
58% for adenocarcinoma. Although the difference was statis-
tically signiﬁcant on univariate analysis it was not statistically
signiﬁcant when multivariate analysis was applied [41]. Simi-
larly, the incidence of distant metastasis in urothelial cancer
ranged from 12% to 35% [42,43].
Loco-regional recurrence with or without distant metastasis
was found in 5–31% of the patients treated with RC, depend-
ing on their pathological and clinical features [44]. Factors
associated with local recurrence are mostly the same as those
determining distant metastasis, namely pathologic tumor
stage, grade and regional nodal involvement together with
the lymphadenectomy extent. Rates of local recurrence were
reported in SNA-BC as 6, 18 and 51% in patients with stage
pT1, pT2 and pT3, respectively [44]. Another SNA-BC study
showed that the 5-year local recurrence rate reached 11, 23
and 31% for stages II, III and IV, respectively [45]. In a third
study, the 10-year local recurrence rate was reported to be 25%
for pT3, 51% for pT4 and 49% in node-positive patients [46].
Volkmer et al. [47] showed that the 10-year recurrence rate was
48.6%. Out of the relapsed 41% developed local recurrence
and 324 (73%) had distant metastasis at the time of ﬁrst re-
lapse [47]. On the other hand, Gupta et al. reported 29%
(145/502) who underwent RC developed recurrence [48]. Of
these, 40 (27.6%) patients developed local pelvic recurrence
and 105 (72.4%) developed distant metastasis. Similar results
of loco-regional recurrences were repeatedly reported in SA-
BC [49–53].
Treatment of non-muscle invasive bladder cancer
Non-muscle-invasive bladder cancer comprised Ta (conﬁned
to the mucosa) T1 (invades the lamina propria) as well as ﬂat
high grade tumors that are conﬁned to the mucosa Tis or CIS).
The molecular biology techniques and clinical experience dem-
onstrated the highly malignant, invasive potential of Tis and
T1 lesions. Therefore, the term non-muscle invasive or superﬁ-
cial bladder cancer is suboptimal description [54]. Complete
and correct TURBT (contains the complete tumor plus a part
of the underlying bladder wall), is essential for treatment [55],
Random biopsies from normal-looking mucosa should be per-
formed in patients with positive urinary cytology and absence
of visible tumor. A second TUR should be considered when
the initial resection is incomplete [56]. Adjuvant treatment de-
pends upon risk group classiﬁcation (low, intermediate and
high). This risk classiﬁcation determines progression, motality
and recurrence rates. There is strong evidence that one imme-
diate intravesical chemotherapy instillation signiﬁcantly re-
duces the risk of recurrence in TaT1 tumors. Mitomycin C,
epirubicin and doxorubicin showed beneﬁcial effect and none
of them is superior to the others [54]. The choice between fur-ther chemotherapy or immunotherapy (BCG) instillation de-
pends largely on risk status. For intermediate and high-risk
tumors adjuvant BCG proved to be superior to chemotherapy
for tumor recurrence prevention [57]. Although this treatment
type is very popular in urothelial cancer, it is less popular in
SA-BC and non-urothelial SNA-BC. This may be due to the
prevalence of many precancerous or cancerous lesions in the
bladder mucosa, and the fewer number of non-invasive stages
in these patients [58].
The European Association of Urology (EAU) [54] advo-
cated cystectomy for multiple recurrent high-grade tumors,
BCG treatment failures, high-grade T1 and high-grade tumors
with concurrent CIS. Delay of cystectomy in these patients
might lead to decreased disease-speciﬁc survival [54]. Ali-El-
Dien et al. [59] conﬁrmed the value of this recommendation
in 204 urothelial cancer patients including SA-BC and NSA-
BC.
Treatment of muscle-invasive bladder cancer
Radical cystectomy
Muscle-invasive bladder cancer is mostly treated with radical
cystectomy in many parts of the world. Radical cystectomy
procedure includes removal of the bladder, seminal vesicles
and prostate together with perivesical fat and peritoneal cover-
age, in addition to the varying level of pelvic lymphadenec-
tomy in male patients. In females, it includes removal of the
bladder, its perivesical fat and peritoneal coverage, urethra,
uterus, ovary and anterior wall of the vagina (anterior pelvic
exenteration) [52,53,60]. Reviewing recent literature of treat-
ment end-results of different bladder cancer categories; showed
that applying the same treatment yielded nearly the same level
of results in the same pathological stage [51,61]. The 5-year
overall survival rates were similar in SA-BC, pure urothelial
and combined urothelial and non-urothelial SNA-BC types.
The results were slightly higher in Stein et al. [60] (NSA-BC)
and Zaghloul et al. [51] (SA-BC) probably due to adding neo-
adjuvant or adjuvant radiotherapy and /or chemotherapy in
more than one third of their patients (see Table 1). The same
conclusion applies for a comparison of disease-free survival,
overall survival, or local control rates for radical cystectomy
or even in adjuvant and neoadjuvant radiotherapy types of
treatment for SA-BC and SNA-BC [51,61]. The treatment
end-results of radical cystectomy was not affected by the asso-
ciation with schistosomiasis, nor tumor cell type (urothelial or
non-urothelial) in most published literature [51,60,62]. These
results were constant for both SA-BC (ranged from 47% to
83%), and SNA-BC (ranged from 50% to 84%) and signiﬁ-
cantly worse when reporting upon locally advanced tumors
(PT3N0M0, PT4aN0M0 or Any N). These worse results were
experienced by both SA-BC and SNA-BC patients
[51,60,62,63]. In spite of the old belief that aberrant differenti-
ation leads to worse results, yet many authors reported similar
results of these variants to UC when comparing stage to stage.
Rogers et al. [64] reported a 5-year progression-free survival
rate of 60 ± 2% after radical cystectomy for UC and
55 ± 11% for SCC. This difference was not statistically signif-
icant. Patients with UC or SCC had statistically signiﬁcant
higher progression-free survival rates than non-UC non-SCC
patients including those having adenocarcinoma. A second
study containing a considerable number of adenocarcinoma
156 M.S. Zaghloulpatients was conducted using 17 Surveillance, Epidemiology
and End Results (SEER), showed no difference of statistical
signiﬁcance in adenocarcinoma patients who underwent RC
than their UC counterparts. A third study using a similar
SEER database demonstrated that SCC was more aggressive
than urothelial cancer after adjusting for common prognostic
factors, such as stage and grade [65]. Scosyrev et al. [65] con-
cluded that SCC was an independent predictor of mortality
among patients with stages III and IV disease, and among pa-
tients with stages I and II disease who did not undergo cystec-
tomy as part of their treatment. Therefore, squamous
histology per se was not associated with increased mortality
among patients with stages I and II disease when treated with
cystectomy. Furthermore, Ploeg et al. [66] studied all invasive
bladder cancer cases treated in The Netherlands during a
12 year period. They concluded that the relative survival of
muscle-invasive adenocarcinoma patients was equal to that
of UC patients. For stages II and III disease, adenocarcinoma
patients had even better outcome. Muscle-invasive SCC pa-
tients showed worse survival regardless of stage. In SA-BC,
Ghoneim et al. [53] demonstrated that SCC (1345 patients)
had 10 year overall survival rate (OS) of 53% compared to
48% for pure UC (705 patients) and 51% for adenocarcinoma
(262 patients). Those patients who had UC with squamous or
adenomatous metaplasia (286 patients) showed a lower 10-
year OS of 43%. The lowest 10-year OS was experienced by
those patients who had undifferentiated pathology (122 pa-
tients) having 10-year OS of 34. It is clear from this large-num-
ber single institution study that the OS of SCC, UC and
adenocarcinoma were similar and having the same proﬁle as
that of SNA-BC. The multivariate analysis proved that tumor
cell type is not an independent working factor determining the
OS. Many authors cautiously concluded that RC treatment
end-results were not affected by tumor histology or etiology
but affected by other prognostic factors like stage, grade, no-
dal involvement, lymphovascular invasion, angiogenesis, P53,
P21, Retinoblastoma genes (Rb) and other biological factors.
These prognostic and predictor factors were shown in many
SA-BC and SNA-BC studies [53,61,65,66].
Preoperative and postoperative radiotherapy
The rationale of preoperative radiotherapy is to prevent intra-
operative seeding of tumor cells in the operative ﬁeld and to
sterilize microscopic residue in the perivesical tissues. In the
English literature, only six randomized trials addressed the is-
sue of preoperative radiotherapy to RC. Two of these 6 studies
were on SA-BC patients [67,68]. Only one [67] out of the 6 tri-
als showed the beneﬁt of preoperative radiotherapy. Most of
the other 5 studies revealed that the effect was restricted to
high stage and high grade tumors, with no difference in early
cases. Meta-analysis of these randomized studies showed a cor-
rected odd ratio of 0.94, indicating absence of beneﬁt for add-
ing preoperative radiotherapy to RC [69].
Postoperative radiotherapy (PORT] has the advantage of
dealing with microscopic cells that are easier to sterilize. It al-
lows better identiﬁcation of the group of patients that may
beneﬁt from such adjuvant therapy. One large prospective ran-
domized trial proved the beneﬁt of PORT in locally advanced
SA-BC. The 5-year disease-free survival (DFS) rate was 49 and
44% for PORT conventional (CF) and hyperfractionated
(HF), respectively compared with 25% for cystectomy alonepatients [50]. This effect was constant across all tumor cell
type, all muscle-invasive stages and grades in SA-BC. Nearly
identical results were replicated in a non-randomized prospec-
tive controlled Radiation Therapy Oncology Group (RTOG)
trial on SNA-BC [70]. The results of the 2 studies proved to
be nearly identical when compared stage by stage [39]. The
only difference was that the RTOG trial reported high GIT
late complication rate [70]. Intestinal obstruction was reported
in 37% (15 out of 40 patients) after PORT. Nine out of these
15 patients required surgery and 3 died. On the contrary,
Zaghloul et al. [50] reported 5% and 18% of all grades of late
GIT complications for the HF and CF respectively. Only 4%
and 5% out of the HF and CF group respectively necessitated
surgical interference. Similarly, low levels of late GIT compli-
cations were experienced by other retrospective studies re-
ported on SA-BC and SNA-BC [71–73]. This difference
between the late GIT complications was related to the differ-
ence in radiation volume in different studies and not to associ-
ation with schistosomiasis [61].
In a prospective randomized trial, Abdel Moneim et al. [74]
compared preoperative and postoperative radiotherapy in SA-
BC. They administered the same dose of 50 Gy in 5 weeks to
both groups. The study reported both similar treatment end-
results and similar late complication rates for the pre- and
postoperative radiotherapy. The EAU expected that with the
availability of recent radiotherapy equipment and techniques
allowing for more precise targeting and less damage to the sur-
rounding normal tissues. The EUA and others invite a serious
revisit to the option of pre and post-operative radiotherapy
[58,74–76]
Neoadjuvant and adjuvant chemotherapy
Neoadjuvant and adjuvant chemotherapy have been utilized in
bladder cancer, in an attempt to improve the outcome for pa-
tients with high risk muscle-invasive disease. Several meta-
analysis indicated that patients who underwent neoadjuvant
chemotherapy with methotrexate, vinblastine, doxorubicin
and cisplatin (MVAC) prior to cystectomy have a 5.0–6.5%
survival advantage over those who underwent surgery alone
[77,78]. However, some investigators continue to argue that
this neoadjuvant advantage is small and chemotherapy might
be better targeted to those at the highest risk of relapse after
surgery. Many elderly patients or those having comorbidities
will not tolerate MVAC chemotherapy. Therefore, many
investigators tried adjuvant chemotherapy in supposing more
favorable situation. In reality, adjuvant chemotherapy yielded
a modest, statistically signiﬁcant improvement in the survival
of SNA-BC patients over cystectomy alone [79,80].
The Egyptian bladder cancer cooperative group compared
neoadjuvant chemotherapy using a more tolerable gemcita-
bine–cisplatin regimen to cystectomy alone in 109 SA-BC pa-
tients. The one-year survival rate was 54% for the
cystectomy alone patients compared to 69% for the neoadju-
vant chemotherapy patients [81]. However, this difference
did not rank to the level of signiﬁcance.
Bladder preservation trimodality treatment
Since the 1980s, many centers investigated the bladder preser-
vation strategy as an alternative to radical cystectomy. The
rationale of this strategy depends on 3 goals: eradication of
Bladder cancer and schistosomiasis 157the local disease, elimination of potential micrometastasis and
maintenance of the best possible quality of life (QoL) through
organ preservation [82]. Variable treatment protocols were car-
ried out by different investigators. However, they all com-
prised 3 essential procedures. The ﬁrst main procedure is
maximal TURBT, to be followed by the second procedure:
neoadjuvant chemotherapy or radiochemotherapy and fol-
lowed by cystoscopic assessment. The third procedure is either
consolidation radiochemotherapy for the complete responders
or cystectomy. Cystoscopic assessment will segregate the com-
plete responder (CR) for bladder-conserving management and
those showing less than CR to undergo salvage cystectomy
[83]. The 5-year OS rates ranged between 39% and 58% and
the 5-year survival with native bladder preservation ranged
from 36% to 43% [83–88]. Sabaa et al. [89] reported similar re-
sults for UC (SA-BC and SNA-BC) in Egypt using a trimodal-
ity treatment. Complete remission was achieved in 79% of
cases after initial radiochemotherapy using gemcitabine–cis-
platin regimen. The 5-year OS rate for patients with initial
CR was 68% which is comparable to that obtained in SNA-
BC in the western countries treated with the same modality.
Sabaa et al. [74] emphasized that the association with schisto-
somiasis had no signiﬁcant impact on the results of therapy for
their patient. Similarly, Aboziada et al. [90] reached to the
same conclusion though in a relatively smaller number of pa-
tients and shorter follow up.
Conclusions
With the continuous advancement in health care in schisto-
soma-endemic areas, the management of SA-BC followed, to
a great extent, the recommendations for urothelial tumors.
The application of evidence-based recommendations in the
management of bladder cancer regardless of its etiology
may improve the treatment end-results including the quality
of life. The availability of a large number of patients will al-
low the determination of a recommended risk-adapted ther-
apy that minimizes the under- or over-treatment for such
patients.
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